- Home
- WDC vs GILD Comparison
WDC vs GILD Comparison
Compare WDC & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WDC | GILD |
|---|---|---|
| Founded | 1970 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.4B | 168.6B |
| IPO Year | 1999 | 2003 |
Fundamental Metrics
Financial Performance| Metric | WDC | GILD |
|---|---|---|
| Price | $742.29 | $123.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 18 |
| Target Price | ★ $281.77 | $148.39 |
| AVG Volume (30 Days) | 6.0M | ★ 6.9M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | 0.12% | ★ 2.55% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | ★ 16.05 | 1.61 |
| Revenue | $9,520,000,000.00 | ★ $24,689,000,000.00 |
| Revenue This Year | $32.24 | $4.68 |
| Revenue Next Year | $26.55 | $6.04 |
| P/E Ratio | ★ $44.38 | $77.59 |
| Revenue Growth | N/A | ★ 9.98 |
| 52 Week Low | $58.97 | $107.30 |
| 52 Week High | $741.85 | $157.29 |
Technical Indicators
Market Signals| Indicator | WDC | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 78.19 | 38.01 |
| Support Level | $457.44 | $116.55 |
| Resistance Level | N/A | $126.46 |
| Average True Range (ATR) | 41.39 | 3.67 |
| MACD | 17.74 | -0.29 |
| Stochastic Oscillator | 83.52 | 13.49 |
Price Performance
Historical ComparisonAbout WDC Western Digital Corporation
Western Digital is a leading vertically integrated supplier of hard disk drives. The HDD market is a practical duopoly, with Western Digital and Seagate being the two largest players. Western Digital designs and manufactures its HDDs, with much of the manufacturing and workforce located in Asia. The primary consumers of HDDs are data centers.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).